T2-3N0 or T1-2N1
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| PD-1 Combined With Intensity Modulated Radiation Therapy in the Treatment of Intermediate-risk Nasopharyngeal Carcinoma (NCT05229315) | XIANG YANQUN | 2022-03-12 |
Track T2-3N0 or T1-2N1 automatically
Every clearance here is in the API, with alerts when new ones post.